The clinical value of metabolic syndrome and its components with respect to sudden cardiac death using different definitions: Two decades of follow-up from the Tehran Lipid and Glucose Study

Table 4 HRs and 95% CIs showing the relationship of different definitions of metabolic syndrome with incidence of sudden cardiac death: Tehran Lipid and Glucose Study (1999–2018)

	E/N	Model 1		Model 2		Model 3		Model 4
	E/N	HR (95% CI)	P-value	HR (95% CI)	P-value	HR (95% CI)	P-value	HR (95% CI)	P-value
MetS (JIS)	109/2581	1.42 (1.05–1.92)	0.02	1.47 (1.08–1.98)	0.01	–	–	0.88 (0.50–1.55)	0.66
MetS (IDF)	82/1782	1.50 (1.12–2.02)	0.01	1.51 (1.12–2.03)	0.01	–	–	0.74 (0.40–1.38)	0.34
MetS (ATP III)	89/2296	1.34 (0.99–1.81)	0.06	1.36 (1.00–1.85)	0.05	1.06 (0.76–1.47)	0.73	0.81 (0.46–1.42)	0.36
MetS (WHO)	80/1342	2.07 (1.53–2.80)	< 0.01	2.10 (1.55–2.86)	< 0.01	1.68 (1.20–2.35)	< 0.01	1.23 (0.58–2.62)	0.59

Model 1: Adjusted for age + sex
Model 2: Model 1 + smoking + resting heart rate + family history of premature CVD
Model 3: Model 2 + antihypertensive medications (only for ATP III definition) + lipid-lowering medications + glucose-lowering medications
Model 4: Further adjustment with MetS components
HR hazard ratio, CI confidence interval, MetS metabolic syndrome, JIS joint interim statement, IDF International Diabetes Federation, ATP III Adult Treatment Panel III, WHO World Health Organization
N Subjects with metabolic syndrome for each definition
E Number of SCD events

ISSN: 1475-2840